Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost

BACKGROUND: We report the first-in-human safety and immunogenicity evaluation of PENNVAX-G DNA/modified vaccinia Ankara–Chiang Mai double recombinant (MVA-CMDR) prime-boost human immuonodeficiency virus (HIV) vaccine, with intramuscular DNA delivery by either Biojector 2000 needle-free injection sys...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Infect Dis
Main Authors: Ake, Julie A, Schuetz, Alexandra, Pegu, Poonam, Wieczorek, Lindsay, Eller, Michael A, Kibuuka, Hannah, Sawe, Fredrick, Maboko, Leonard, Polonis, Victoria, Karasavva, Nicos, Weiner, David, Sekiziyivu, Arthur, Kosgei, Josphat, Missanga, Marco, Kroidl, Arne, Mann, Philipp, Ratto-Kim, Silvia, Anne Eller, Leigh, Earl, Patricia, Moss, Bernard, Dorsey-Spitz, Julie, Milazzo, Mark, Laissa Ouedraogo, G, Rizvi, Farrukh, Yan, Jian, Khan, Amir S, Peel, Sheila, Sardesai, Niranjan Y, Michael, Nelson L, Ngauy, Viseth, Marovich, Mary, Robb, Merlin L
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Major Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5853809/
https://ncbi.nlm.nih.gov/pubmed/28968759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jix456
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados